Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach

References

• Fitch Solutions Macro Research. Saudi Arabia pharmaceuticals & healthcare report q4. London, UK: Business Monitor International Ltd; 2018. UK Company. [cited 2020 Mar 10]. Available from: https://store.fitchsolutions.com/all-products/saudi-arabia-pharmaceuticals-healthcare-report
   Google Scholar
• The World Bank Group. World bank open data. Washington DC, USA: The World Bank Group; 2019 [cited 2020 May 12]. Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=SA
   Google Scholar
• The United Nations. Un data: saudi Arabia general information. New York, USA: United Nations Statistics Division; 2020. [cited 2020 May 12]. Available from: https://data.un.org/en/iso/sa.html
   Google Scholar
• Schumock GT, Stubbings J, Wiest MD, et al. National trends in prescription drug expenditures and projections for 2018. Am J Health Syst Pharm. 2018 Jul 15;75(14):1023–1038. PubMed PMID: 29748254.
   PubMed Web of Science ®Google Scholar
• Gronde TV, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One. 2017;128:e0182613. PubMed PMID: 28813502; PubMed Central PMCID: PMCPMC5559086.
   PubMed Web of Science ®Google Scholar
• McMahon V. Costs of gene therapy for spinal muscular atrophy assessed at ISPOR. PharmacoEcon Outcomes News. 2019 Jun 1;830(1):12–13.
   Google Scholar
• Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009 Aug 5;101(15):1044–1048. PubMed PMID: 19564563; PubMed Central PMCID: PMCPMC2724853. eng.
   PubMedGoogle Scholar
• Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014 Mar;15(3):e112–8. PubMed PMID: 24534294; eng.
   PubMed Web of Science ®Google Scholar
• Kanavos P, Ferrario A, Tafuri G, et al. Managing risk and uncertainty in health technology introduction: the role of managed entry agreements. Global Policy. 2017;8(S2):84–92.
   Web of Science ®Google Scholar
• Morel T, Arickx F, Befrits G, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: A comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis. 2013 Dec 24;8(1):198. PubMed PMID: 24365263; PubMed Central PMCID: PMCPMC3882782.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: justum pretium–the just price. J Clin Oncol. 2013 Oct 1;31(28):3600–3604. PubMed PMID: 23650428; PubMed Central PMCID: PMCPMC3782152. eng.
   PubMed Web of Science ®Google Scholar
• Europe WHO. Access to new medicines in Europe: technical review of policy initiatives, opportunities for collaboration and research. 2015.
   Google Scholar
• McCabe CJ, Stafinski T, Edlin R, et al. Access with evidence development schemes: A framework for description and evaluation. Pharmacoeconomics. 2010;28(2):143–152. PubMed PMID: 20085390; eng.
   PubMed Web of Science ®Google Scholar
• Robinson MF, Mihalopoulos C, Merlin T, et al. Characteristics of managed entry agreements in australia. Int J Technol Assess Health Care. 2018 Jan;34(1):46–55. PubMed PMID: 29277174; eng.
   PubMed Web of Science ®Google Scholar
• Piatkiewicz TJ, Traulsen JM, Holm-Larsen T. Risk-sharing agreements in the EU: A systematic review of major trends. Pharmacoecon Open. 2018 Jun;2(2):109–123. PubMed PMID: 29623619; PubMed Central PMCID: PMCPMC5972115. eng.
   PubMed Web of Science ®Google Scholar
• Klemp M, Fronsdal KB, Facey K, et al. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care. 2011 Jan;27(1):77–83. PubMed PMID: 21262072; eng.
   PubMed Web of Science ®Google Scholar
• Antonanzas F, Juarez-Castello C, Lorente R, et al. The use of risk-sharing contracts in healthcare: theoretical and empirical assessments. Pharmacoeconomics. 2019 Dec;37(12):1469–1483. PubMed PMID: 31535280.
   PubMed Web of Science ®Google Scholar
• de Pouvourville G. Risk-sharing agreements for innovative drugs: A new solution to old problems? Eur J Health Econ. 2006 Sep;7(3):155–157. PubMed PMID: 16912890; eng.
   PubMedGoogle Scholar
• Goncalves FR, Santos S, Silva C, et al. Risk-sharing agreements, present and future. Ecancermedicalscience. 2018;12:823. PubMed PMID: 29743943; PubMed Central PMCID: PMCPMC5931811. eng.
   PubMed Web of Science ®Google Scholar
• Gerkens SNM, San Miguel L, Vinck I, et al. How to improve the belgian process for managed entry agreements? An analysis of the belgian and international experience. KCE Reports 288. Brussels, Belgium: Belgian Health Care Knowledge Centre (KCE); 2017 [cited 2020 Mar 7]. Available from: https://kce.fgov.be/sites/default/files/atoms/files/KCE_288_Improve_Belgian_process_managed_entry_agreements_Report.pdf
   Google Scholar
• Walker S, Sculpher M, Claxton K, et al. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012 May;15(3):570–579. PubMed PMID: 22583469; eng.
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Sullivan SD, Garrison LP, et al. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010 Aug;96(3):179–190. PubMed PMID: 20226559; eng.
   PubMed Web of Science ®Google Scholar
• Grimm S, Strong M, Brennan A, et al. Framework for analysing risk in health technology assessments and its application to managed entry agreements. Sheffield, UK: University of Sheffield.; 2016 [cited 2020 Mar 10]. Available from: http://nicedsu.org.uk/wp-content/uploads/2018/05/DSU-Managed-Access-report-FINAL.pdf
   Google Scholar
• Brügger U. A review of coverage with evidence development (CED) in different countries: what works and what doesn’t Manchester. UK: NICE; 2014 [cited 2020 Mar 8]. Available from: https://htai.org/wp-content/uploads/2018/02/CED_Report_Bruegger_Final_Version.pdf
   Google Scholar
• Ferrario A, Araja D, Bochenek T, et al. The implementation of managed entry agreements in central and eastern Europe: findings and implications. Pharmacoeconomics. 2017 Dec;35(12):1271–1285. PubMed PMID: 28836222; PubMed Central PMCID: PMCPMC5684278. eng.
   PubMed Web of Science ®Google Scholar
• Nazareth T, Ko JJ, Sasane R, et al. Outcomes-based contracting experience: research findings from U.S. and European stakeholders. J Manag Care Spec Pharm. 2017 Oct;23(10):1018–1026. PubMed PMID: 28944734; eng.
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Chen S, Garrison LP Jr. Performance-based risk-sharing arrangements: an updated international review. Pharmacoeconomics. 2017 Oct;35(10):1063–1072. PubMed PMID: 28695544; eng.
   PubMed Web of Science ®Google Scholar
• Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in belgium, England, the netherlands and sweden. Soc Sci Med. 2015 Jan;124:39–47. PubMed PMID: 25461860; eng.
   PubMed Web of Science ®Google Scholar
• Yu JS, Chin L, Oh J, et al. Performance-based risk-sharing arrangements for pharmaceutical products in the United States: A systematic review. J Manag Care Spec Pharm. 2017 Oct;23(10):1028–1040. PubMed PMID: 28944733; eng.
   PubMed Web of Science ®Google Scholar
• Darba J, Ascanio M. The current performance-linked and risk sharing agreement scene in the spanish region of catalonia. Expert Rev Pharmacoecon Outcomes Res. 2019 Dec;19(6):743–748. PubMed PMID: 30821532.
   PubMed Web of Science ®Google Scholar
• Pauwels K, Huys I, Vogler S, et al. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;8:171. PubMed PMID: 28420990; PubMed Central PMCID: PMCPMC5378787. eng.
   PubMed Web of Science ®Google Scholar
• Garattini L, Casadei G. Risk sharing agreements: what lessons from Italy? Int J Technol Assess Health Care. 2011 Apr;27(2):169–172. PubMed PMID: 21429288; eng.
   PubMed Web of Science ®Google Scholar
• Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. European Medicines Information Network (EMINet),Brussels, Belgium; 2013.
   Google Scholar
• Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015 Jan;16(1):1–3. PubMed PMID: 24728513; eng.
   PubMed Web of Science ®Google Scholar
• Lu CY, Lupton C, Rakowsky S, et al. Patient access schemes in asia-pacific markets: current experience and future potential. J Pharm Policy Pract. 2015 February 16;8(1):6. PubMed PMID: 25815200; PubMed Central PMCID: PMCPMC4359387.
   PubMedGoogle Scholar
• Maskineh C, Nasser SC. Managed entry agreements for pharmaceutical products in Middle East and north african countries: payer and manufacturer experience and outlook. Value Health Reg Issues. 2018 Sep;16:33–38. PubMed PMID: 29936067; eng.
   PubMedGoogle Scholar
• Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006 January 01;3(2):77–101.
   Google Scholar
• Haas JS, Moskowitz EJ. Health technology assessment in Canada and the United States: the case of biologics. Biotechnol Healthc. 2007 Apr;4(2):47–51. PubMed PMID: 23372511; PubMed Central PMCID: PMCPMC3555186. eng.
   PubMedGoogle Scholar
• Bouvy JC, Sapede C, Garner S. Managed entry agreements for pharmaceuticals in the context of adaptive pathways in Europe. Front Pharmacol. 2018;9:280. PubMed PMID: 29636692; PubMed Central PMCID: PMCPMC5881456. eng.
   PubMed Web of Science ®Google Scholar
• Navarria A, Drago V, Gozzo L, et al. Do the current performance-based schemes in Italy really work? “Success fee”: A novel measure for cost-containment of drug expenditure. Value Health. 2015 Jan;18(1):131–136. PubMed PMID: 25595244; eng.
   PubMed Web of Science ®Google Scholar
• Coulton L, Annemans L, Carter R, et al. Outcomes-based risk-sharing schemes: is there a potential role in the Asia-Pacific markets? Health Outcomes Res Med. 2012 Nov 1;3(4):e205–e219.
   Google Scholar
• Garrison LP Jr., Carlson JJ, Bajaj PS, et al. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am J Manag Care. 2015 Sep;21(9):632–640. PubMed PMID: 26618366; eng.
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr., Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013 Jul-Aug;16(5):703–719. PubMed PMID: 23947963; eng.
   PubMed Web of Science ®Google Scholar
• Hutton J, Trueman P, Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007 Fall;23(4):425–432. PubMed PMID: 17937829.
   PubMed Web of Science ®Google Scholar
• Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010 Jun 7;10(1):153. PubMed PMID: 20529296; PubMed Central PMCID: PMCPMC2906457.
   PubMed Web of Science ®Google Scholar
• Morgan SG, Vogler S, Wagner AK. Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in north America, Europe, and australasia. Health Policy. 2017 Apr;121(4):354–362. PubMed PMID: 28238340; eng.
   PubMed Web of Science ®Google Scholar
• Al-Omar HA, Attuwaijri AA, Aljuffali IA. What local experts expect from a health technology assessment (HTA) entity in Saudi Arabia: workshop conclusions. Expert Rev Pharmacoecon Outcomes Res. 2020 Feb;20(1):99–104. PubMed PMID: 31032687.
   PubMed Web of Science ®Google Scholar
• Al-Omar HA, Attuwaijri AA, Aljuffali IA. Pharmaceutical companies' views on a health technology assessment (HTA) entity in Saudi Arabia. Saudi Pharm J. 2020 Jun;28(6):662-668. doi: 10.1016/j.jsps.2020.04.006. PubMed PMID: 32550796; PubMed Central PMCID: PMCPMC7292859.
   Google Scholar
• Vogler S, Paris V, Ferrario A, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017 Jun;15(3):307–321. PubMed PMID: 28063134; eng.
   PubMed Web of Science ®Google Scholar